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1. Introduction
A tumor consists of a population of rapidly dividing and growing cancer cells. Cancer cells
have lost their ability to divide in a controlled fashion and as a consequence they rapidly
accumulate mutations. In such way cancer cells (or sub-populations of cancer cells within a
tumor) will acquire stronger proliferative capacity [1]. Tumors cannot grow beyond a certain
size due to a lack of oxygen and other essential nutrients. Tumors cells have then acquired a
specific feature that is to induce blood vessel growth, a process called tumor angiogenesis.
Tumor angiogenesis is a necessary and required step for transition from a small harmless
cluster of cells to a large tumor [2]. The early induction of tumor vasculature is termed
“angiogenic switch”, that occurs when a tumor mass reaches about dimensions of 2 mm2 and
moves towards progression. The “angiogenic switch” is a rate-limiting step for tumor growth
that is not limited at earliest stages, but occurs also at different stages of tumor-progression.
The angiogenic switch induces angiogenic sprouting and new vessels formation and matura‐
tion. Activation of angiogenesis in premalignant lesions and dormant metastasis is mandatory
for tumor survival. The fact that tumor mass is depending on angiogenesis has driven the
medical research towards the characterization of molecular pathways and cellular dynamics
for the induction and regulation of angiogenesis.
Tumor angiogenesis is regulated by several growth factors (EGF, TGFα, bFGF, VEGF).
Induction of these angiogenic factors is triggered by various stresses [3]. For instance, tissue
hypoxia exerts its pro-angiogenic action through various angiogenic factors, the most notable
is VEGF (vascular endothelial growth factor), which has been mainly associated with initiating
the process of angiogenesis through the recruitment and proliferation of endothelial cells [4].
Recently, reactive oxygen species (ROS) have been found to stimulate angiogenic response in
the normal and pathological angiogenesis. ROS can cause tissue injury in one hand and
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promote tissue repair in another hand by promoting angiogenesis. It thus appears that after
causing injury to the cells, ROS promptly initiate the tissue repair process by triggering
angiogenic response. Recently, it has been reported that redox signaling may influence
pathological angiogenesis as well [5,6].
2. Redox signaling in normal and pathological angiogenesis
Redox signaling is a biochemical communication by free radicals, reactive oxygen species
(ROS), and other electronically activated species such as nitric oxide and other oxides of
nitrogen acting as biological messengers [7]. Pro- and anti-oxidative species act as second
messengers. Pro-oxidative species are physiologically produced by cells and tightly regulated
with antioxidant systems. Down-regulation of antioxidant system or up-regulation in pro‐
duction of pro-oxidative species leads to oxidative stress state. This condition is reported as
dangerous for cells since it conveys macromolecules damage. Importantly, it has been reported
that oxidative stress plays a key role in the regulation of tumor angiogenesis [8]. The complex
molecular network that regulates endothelial cells homeostasis during angiogenesis includes
molecules sensitive to redox state of biological environment. The redox state is determined by
the relative abundance of highly chemically reactive species derived from oxygen (ROS:
Reactive Oxygen Species) or nitrogen (RNS: Reactive Nitrogen Species) (Table 1).
Table 1. List of oxygen (ROS) and nitrogen (RNS) reactive species commonly found in normal and pathological tissues.
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Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are important in regulation
of cell survival. In general, moderate levels of ROS/RNS functions as signals to promote cell
proliferation and survival, whereas severe increase of ROS/RNS can induce cell death. Under
physiologic conditions, the balance between generation and elimination of ROS/RNS main‐
tains the proper function of redox-sensitive signaling proteins. Normally, the redox homeo‐
stasis ensures that cells respond properly to endogenous and exogenous stimuli. However,
when the redox homeostasis is disturbed, oxidative stress may lead to aberrant cell death and
contribute to disease development [9].
Reactive species are highly reactive chemical molecules or ions, characterized by unpaired
electrons that react with other molecules in order to stabilize their electron configuration and
gain a more stable state. Consequently, the reaction of ROS/RNS with cellular molecules is a
damaging reaction of oxidation. Oxidized molecules are dysfunctional and may induce cell
death. Initially, the presence of ROS/RNS was linked only to cellular damage and cell degen‐
erative processes. However, accumulating evidences derived from the characterization of
mechanisms for buffering and regulating reactive species opened the possibility that oxidative
species are important for cellular homeostasis. Reactive species had been also described as
second messenger molecules and their interaction with molecules is identified as a post-
translational modification (i.e. S- nitrosylation of proteins) that can trigger a specific intracel‐
lular signal. At the present, the evidence is that a tight regulation of pro-oxidative species levels
is essential for cellular homeostasis and that such regulatory mechanism is fundamental to
maintain a safe redox state and activate related redox signaling pathways [10].
In vascular beds, the redox state is mainly modulated by oxygen concentration and by
mechanical forces (i.e. shear stress caused by blood flow) [11]. In normal conditions oxygen
levels are constant and essential to guarantee sufficient provision for tissues oxygenation.
Mechanisms for sensing oxygen tension are based on redox-mediated signaling. During
normoxic conditions the transcription factor HIF1α (hypoxia inducible factor) is degraded in
a ROS-dependent manner, while during hypoxia the concentration of oxygen is lower and
ROS levels are differentially modulated. Consequently, HIF1α couples with HIF1β and
activates transcription of genes involved in angiogenesis, vascular remodeling and cell
proliferation [12].
Redox signaling events are also activated in endothelial cells during normal angiogenesis for
sensing mechanical forces. Shear forces are constantly present on endothelial cells where
regulate cell proliferation, survival and migration. Vascular forces exercise a mechanical
stimulus that is perceived by endothelial cells and translated into intracellular molecular
pathways. Therefore, concomitant to shear forces there is an upregulation in production of
RNS and ROS. In adult ECs, the mechanical oscillatory shear stress induces the activation of
specific antioxidant enzymes or proteins like peroxiredoxins (Prx) that act as “mechano-
sensitive antioxidants” [13]. Moreover, specific antioxidant and protective genes are induced.
Shear stress causes upregulation of specific “antioxidant transcriptional factors” Nrf2 and ATF
in developing embryonic vasculature as well as in adult ECs [14]. Most of the molecules with
oxidative properties that modulate endothelial cell homeostasis in normal conditions are
included in redox molecular pathways that are altered in pathogenic angiogenesis [15]. There
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are specific oxidized products or redox sensitive proteins that behave differentially. ROS-
activated factors play different role in context of pathologic angiogenesis or normal angio‐
genesis. The ATM kinase protein, which is involved in regulation of endothelial cells survival
and proliferation is activated in tumor condition under upregulation of ROS and promotes
new vessel formation, while it is not activated in normal vasculature [16]. Oxidative stress
triggered by inflammation in tumor conditions (i.e. human melanoma) causes lipid peroxida‐
tion with consequent accumulation of an oxidized compound: ω-(2-carboxyethyl)-pyrrole
(CEP). The CEP acts as a ligand for Toll-like receptor 2 (TLR2) and induces angiogenesis
independently from VEGF [17]. Similarly, oxidized lipid (carboxyalkyl pyrroles, CAPs)
molecules bind to their TLRs receptors and activate angiogenesis in some specific pathological
conditions such us age related macular degeneration [18].
In the following three different paragraphs we will define the cellular systems regulating redox
signaling and how they control molecules and factors clearly involved in angiogenesis. In
addition, here we plan to present paragraphs about main sources for production of oxidative
species and systems for counteract their products and maintenance of an equilibrated cell
redox state. Finally, we will describe molecules sensitive to redox signaling that are known for
being part of established pathway for tumor angiogenesis signaling.
3. Molecules generating oxidative species in endothelial cells
In endothelial cells the endogenous production of pro-oxidative species is mainly generated
by four different enzymes: NADPH oxidases (NOX), Cyclooxygenases (COX), Xanthine
oxidoreductase (XOR), and dysfunctional endothelial NOS (eNOS).
NADPH oxidases (NOX). NADPH oxidases are a family of enzymes composed by seven
members: NOX1, NOX2, NOX3, NOX4, NOX5 and two homologues DUOX1, DUOX2. All of
them are transmembrane proteins containing a NADPH-binding site, a FAD binding region,
heme-binding sites and several subunits that function in the regulation and maturation of
enzymes. p22phox, DUOX activator 1 (DUAX1) and DUOX activator 2 (DUOX2) are important
factors for NOX and DUOX maturation. Among factors important for NOX and DUOX enzyme
activation we found p67phox, NOX activator1 (NOXA1), small GTPase (RAC1 and RAC2). On
the contrary specific regulator of NOX4 is polymerase δ-interacting protein 2 (POLDIP2) and
Ca2+ ions are specific activators of NOX5 and DUOX1/DUOX2 isoforms. These enzymes are
also associated to spatial regulator subunits p40phox, p47phox and NOX organizer1 (NOXO1) that
are important for the enzyme complex structure [19]. NADPH oxidase catalytic activity
consists in the generation of superoxide anions (O2-) through an electrons transfer cycle from
an electron donor (NADPH) to FAD subunit, heme groups and to a final electron acceptor that
is a molecule of oxygen. Activation of NOX4, DUOX1 and DUOX2 results mainly in the release
of hydrogen peroxide instead of superoxide anions. The specific role of this enzyme family
consists in the production and release of pro-oxidative species. Such class of enzymes is
considered one of the main player in the redox signaling in cardiovascular system [20].
NADPH oxidases are expressed in various types of cells along the vascular wall, including
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vascular smooth muscle cells, monocytes and macrophages. NOX1, NOX2, NOX4 and NOX5
are constitutively expressed in the endothelial cells and their functionality is regulated by
several vascular conditions like shear stress, hypoxia or stimuli as hormones, cytokines, pro-
angiogenic factors [21]. It has been demonstrated that NADPH oxidase are sensitive to pro-
angiogenic vascular endothelial growth factor (VEGF) activation and it seems probable that
reactive oxygen species derived from their oxidase activity may sustain activated VEGFR2 and
promote endothelial cells migration and proliferation [22]. In endothelium the regulation of
NOX activity is tightly associated with redox balance, since it has been demonstrated that NOX
are involved with a series of cardiovascular disease like hypertension, atherosclerosis or
ischemia/reperfusion injury [23]. A specific role of NADPH oxidase activity is also reported
during the angiogenesis process [24]. NOX1 activity mediates the interaction between
leukocyte cells and endothelium and is involved in the initiation of cell migration. NOX1 levels
are sensitive to oscillatory shear stress conditions and are positively regulated by HIF-1 and
PDGF. Also NOX1 is involved in angiogenic switch by sustaining VEGF signaling and
upregulation of matrix metalloproteinase production [25]. NOX2 is also sensitive to vascular
pro-angiogenic factors and is reported to be involved in the regulation of ROS signaling for
cytoskeleton organization in ECs migration [26]. NOX4 is the most abundant isoform in
endothelial tissues and is responsible for basal superoxide production. As a matter of fact the
role of NOX4 in vascular tissues is still far from been understood [27]. NOX5 isoform is present
in mammalian cells, but its function can be substituted by other isoforms (i.e. DUOX in
rodents). In vitro studies report upregulation of NOX5 stimulates endothelial cells prolifera‐
tion and organization in microvascular tubules. Also NOX5 is sensitive to pro-angiogenic
stimuli like angiopoietins [28]. Considering vascular pro-angiogenic factors tightly regulate
by NADPH oxidases several inhibitors have been developed as possible approach to modulate
redox signaling in tumor angiogenesis. The most studied NADPH oxidase inhibitors are
apocyanin and diphenyleneiodonium (DPI). They are quite non-specific inhibitors since they
block assembly of enzyme or electron flow. Emerging new inhibitors for endothelial NOX
isoforms are triazolopyrimidines inhibitors such as VAS2870 and VAS3947, whose preliminary
in vitro and in vivo studies have been reported beneficial for endothelium dysfunctions under
oxidative stress [29].
Cyclooxygenases (COX). Cyclooxygenases act in the rate-limiting step of prostanoids
biosynthesis. There are two kinds of enzymes: cyclooxygenase-1 (COX-1) and cyclooxyge‐
nase-2, also known as prostaglandin endoperoxide H synthase -1 and -2 (PGHS-1 and PGHS-2).
Recently, a cyclooxygenase-1 isoenzyme was identified as COX-3 [30]. Prostanoids are lipid
molecules that are produced from all animal cells in response to specific stimuli, like hormones.
After activation COX produce prostanoids from free fatty acids, typically from arachidonic
acid (AA). In particular COX catalyze the bis-oxygenation of AA into the prostaglandin
endoperoxide PGG2, an intermediate molecule that is subsequently converted into different
kinds of prostanoids by specific enzymes that are downstream COX. There are five main
categories of prostanoid molecules and their specific receptors: 1) prostaglandin D2 (PGD2)
whose receptors are named DP1-DP-2; 2) prostaglandin E2 (PGE2) whose receptors are named
EP1-EP4, 3) prostaglandin F2α (PGF2α) whose receptors are named FP, 4) prostaglandin I2
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(PGI2) whose receptors are named IP and 5) thromboxane A2 (TXA2) whose receptors are
named TP. It is also been reported that some categories of prostanoids can bind peroxisome
proliferator-activated receptors (PPARs). PPARs are key activators of prostanoids signaling,
the binding to their specific G-protein linked receptor activates an intracellular second
messenger (i.e. IP3/cAMP/DAG/Ca2+) that starts a molecular pathway, which is characteristic
for each kind of ligand-receptor. Prostanoids are a class of short-life molecules: immediately
after their production they are released outside from cells by specific receptors (prostaglandin
transporters, PTG), allowing them to act in a paracrine or autocrine way. Prostanoids are
implicated in the regulation of several physiological states (i.e. renal system, kidney functions)
such us pathological states (i.e. inflammation, cancer). In the cardiovascular system this class
of molecules is relevant for the homeostasis of the vasculature. Prostanoids differentially
modulate vascular remodeling by direct action on endothelial cells and their progenitors
(endothelial progenitor cells, EPCs) as well as on platelets and smooth muscle cells. Mainly
prostacyclin PGI2 and thromboxane (TXA2) are involved in the regulation of cardiovascular
system homeostasis, even though they act in a different way. PGI2 is synthetized from COX-2
and is a local vasodilator. It also regulates vascular relation by modulation of smooth muscle
cells. Moreover PGI2 limits the aggregation of platelets and favorites angiogenesis by exerting
a direct effect on cellular pathways of EPCs [31,32]. There are contradictory studies on PGI2
action during tumor angiogenesis, it is reported PGI2 induces tumor angiogenesis by binding
to peroxisomes proliferator-activated receptor – δ (PPAR- δ)[33], on the other hand it is also
been reported that healthy tissues have higher levels of PGI synthases than tumor cells. So, it
has been speculated that tumor cells might induce PGI2 in neighboring endothelial cells and
so they take advantage of its angiogenic property for growth. On the contrary, TXA2 is
synthetized from COX-1 in platelets and promotes vasoconstriction and platelets aggregates.
TXA2 plays an important role in tissue repair as well as on pathological conditions by favouring
atherogenesis. Consequently, the ratio between TXA2 and PGI2 is fundamental for the main‐
tenance of physiological homeostasis [34]. In tumor conditions there are also prostanoids
PGE2 and PGF2α, PGD2. Signaling of PGE2 and its receptor is involved in tumor angiogenesis.
PGE2 induces upregulation of metallopeptidase 9 and activates the fibroblast factor receptor
type 1 (FGFR1) [35]. Also PGF2α is considered a prostanoids molecule that sustains tumor
angiogenesis by inducing activation of EGR-1, HIF-1a and VEGF. Regarding PGD2 and its
receptor DP1 there are evidences for their signaling implication in vessels homeostasis, but
there are opposing reports about the role of PGD2 for normal and tumor angiogenesis [36].
While molecular pathways regarding prostanoids signaling in the regulation of vessels
proliferation are not fully described, their metabolism is considered of significant importance
for development of anti-angiogenic drugs. Drugs for modulation of prostanoids levels are
divided into two classes of molecules: 1) inhibitors of prostanoids biosynthetic enzymes (e.g.
limiting prostanoids biosynthesis) and 2) antagonists of prostanoids receptors (e.g. blocking
prostanoids ‘cellular signaling). The most important drugs of the first class molecules are COX
inhibitors like NSAIDs (aspirin, non-selective COX inhibitor) and COXIBs (selective COX-2
inhibitor) whose evidence as chemo preventive agents is yet reported in preclinical studies.
Among inhibitor molecules, there are also available inhibitors of terminal prostaglandin
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synthetize (tPGSs), and in particular for mPGES-1 (microsomal prostaglandin E synthetize -1).
Inhibitors of mPGES-1, like AF3442e, are now at the beginning of clinical trials. Regarding the
second class of drugs, there are many selective and isoform specific molecules. In particular
EP antagonists have been successfully tested for limiting angiogenesis in different kinds of
pathologies: the ONO8711 (EP1 antagonist) has been tested for inhibitory effects on metastasis
and invasion in hepatocellular carcinoma, the EP3 antagonist ONOA23240 has been tested for
limiting metastasis in Lewis lung carcinoma, the EP4 antagonists ONOA23208 and AH23848
have been tested for limiting angiogenesis and metastasis in skin melanoma, colorectal
adenomas, lung carcinoma and ovarian carcinoma. The limits in application of EP antagonists
is the high level of specificity of action: EP isoform antagonists effects are mediated by signaling
related to a specific EP isoform relative expression in a tumor, that is always tissue and tumor
dependent [37]. An alternative approach that is still needs to be validated is the application of
drugs that modulate the activation of PPAR. Even though prostanoids are a heterogeneous
class of molecules whose metabolism and signaling still needs to be largely characterized in
tumors, they are involved in angiogenesis processes and targetable from drugs.
Xanthine oxidoreductase (XOR). Xanthine oxidoreductase is molybdenum-iron-sulfur flavin
hydrolase and, consequently, its essential cofactors are molybdopterin (Mo-Co), two iron-
sulfur centers (Fe2-S2) and flavin adenine dinucleotide (FAD). XOR shifts between two inter-
convertible forms: Xanthine oxidase (XO; EC 1.1.3.22) and Xanthine Dehydrogenase (XDH; EC
1.17.14). XOR enzyme works in the purine degradation pathway where it converts hypoxan‐
thine and xanthine to uric acid. The catalytic reaction consists of an electron flow from
precursor molecules to electron acceptors (cofactors). In the first part of reaction xanthine
reduces XOR at the Mo-Co core and subsequently the Fe2-S2 coordination core mediates the
re-oxidation of XOR by reducing FAD into FADH2. In order to restore FAD+, electrons are
shifted to NAD+ and in turns directly to oxygen. Consequently, the re-oxidation reaction of
XOR yields to two molecules of hydrogen peroxide (H2O2) and two molecules of superoxide
anion (O2-) [38]. XOR enzyme is expressed at highest levels in the gut and in the liver. However,
it has been also detected in the heart and in endothelial cells [39]. Behind purine metabolism,
XOR is reported to be important for redox signaling since superoxide radicals generated as
side products have shown in pathological conditions of cardiovascular system. In vitro
overexpression of XOR in cultured endothelial cells reduces cell viability, proliferation and
ability to generate vascular tubes due to upregulation of ROS levels [40]. It has also been
described that XOR-generated ROS affect heart cardiac contractility by reacting with nitric
oxide and generation of ONOO- species [41] or by regulating myofilaments sensitivity to
Ca2+ [42]. Moreover XOR activity seems to play a role in oxidative state of infusion /reperfusion
injury as well as in myocardial infarction. Treatments with inhibitors of XOR as allopurinol
and oxypurinol are reported as benefic for cardiovascular pathologies related to XOR-
generated ROS overload. Clinical studies have demonstrated that XOR-inhibition diminishes
endothelium dysfunctions by limiting oxidation of molecules and in particular of lipids by
favoring vaso-relaxation. In particular allopurinol treatment improves endothelium functions
in patients with congestive heart failure by reducing plasma levels of malondyaldehyde (i.e.
lipid peroxidation) and improving NO bioavailability [43].
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Endothelial Nitric Oxide Synthase (eNOS). eNOS is one of the three isoform of nitric oxide
synthase family and it is constitutively expressed in endothelial cells. eNOS is important since
it is the major source of endothelial nitric oxide (NO). NOS enzymes work as homodimers with
support of several cofactors. One monomer is linked to flavin adenine dinucleotide (FAD),
nicotinamide adenine dinucleotide phosphate (NADPH), flavin mononucleotide (FMN) and
binds the second monomer at the oxygenase domain that contains a prosthetic heme group.
The second monomer is also linked to cofactors: tetrahydrobiopterin (BH4) and molecular
oxygen. The catalytic activity consists in an electron flow between NOS cofactors where the
substrate: L-arginine is oxidized to L-citrulline with concomitant production of NO. Moreover
calmodulin (CaM) and Ca2+ are essential for functional enzyme [44]. When eNOS is not able
to produce NO due the absence of specific cofactors the reduction of oxygen and concomitant
production of NO are uncoupled. As consequence of uncoupled eNOS the superoxide anion
is produced instead of NO [45]. The importance of eNOS for endothelium homeostasis is
related to NO as well as to its side product O2-. In physiological conditions NO function is
widely characterized as regulator molecule for vasorelaxation and maintenance of healthy
vascular beds. However the level of NO is critical for vascular homeostasis. Low and medium
NO levels are involved in cellular signaling, while high NO levels are related to apoptosis and
cell damage. NO is a gas that diffuse among tissues. NO is a very reactive molecule that
spontaneously reacts with free radicals (i.e. superoxide anions) generating reactive nitrogen
species (RNS) among which the most common is peroxynitrate (ONOO-). Peroxynitrate is a
potent pro-oxidative radical that cause intracellular damage by nitration and S-nitrosylation
of proteins, lipid and DNA [46]. Excessive cellular damage causes severe endothelium
dysfunctions as reported in multiple cases of cardiovascular disease as diabetes and hyper‐
tensions or inflammation [47,48]. eNOS expression and NO are important players for angio‐
genesis not only in physiological conditions, but also in tumor conditions. NO contributes to
angiogenesis by activating intracellular molecular pathway such as the mitogen activated
kinases (MAPK), cyclic GMP (cGMP), and by regulating expression of fibroblast growth factor
(FGF-2) and controlling the balance between metalloprotease (MMP) and their inhibitors in
surrounding tissues. In tumor conditions it has been reported that tumor cells can upregulate
NO levels by induction of specific intracellular NOS isoforms (iNOS and nNOS) in order to
activate NO-dependent angiogenic signaling. Also eNOS is normally expressed by endothelial
tumor cells and is sensitive to multiple factors present in the tumor microenvironment. Pro-
angiogenic factors such as vascular endothelial growth factor (VEGF), sex hormones or
angiopoietins activate eNOS and positively regulate eNOS in endothelial cells through specific
molecular pathways such as 1) Akt-phosphoinositide3 (PI3K) pathway, 2) phospholipase Cγ
(PLCγ)-diacylglicerol (DAG)/Ca2+ 3) adenilate cyclase (AC) -protein kinase A (PKA). Upregu‐
lation of eNOS triggers NO-specific intracellular signaling not only through cGMP, but also
leading to post-translational modifications of proteins to form S-nitrosothiol and, thus,
generating a specific oxidative signaling mediated by S-nitrosylation. An example of such
mechanism is the nitrosylation of caspase 3 that inhibits apoptosis or the nitrosylation of
p21Ras that enforces cGMP signaling by increasing endothelial cell proliferation [49,50].
Supporting evidences for NO involvement in tumor progression come from in vivo studies
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with NOS inhibitors that have demonstrated a peculiar role for NO in sustaining tumor
growth. Anti-metastatic effects have been reported in several kinds of tumors under treatment
with NOS inhibitors NG-methyl-L-arginine (NMMA) and NG – Nitro-L-arginine methyl ester
(L-NAME) [51,52].
Together with these enzymes the mitochondrial  electron transport chain (ETC) has been
recognized as responsible for pro-oxidative species production. The mitochondrial respirato‐
ry chain is one of the first sources of pro-oxidative species to have been characterized in cells.
Mechanism  through  witch  oxidative  species  are  produced  in  mitochondria  are  widely
described as side products of ETC [53,54]. As it has been described ETC consists in an electron
flow among different protein complexes in the inner mitochondria membranes. Electrons
from  NADPH  are  transferred  NADPH-ubiquinone  oxidoreductase  complex  I  which
consequently  transfer  electrons  downstream to  complex  II.  Then,  electrons  according to
electrochemical gradients flow to complexes III and IV. The final step of the chain is the
reduction of oxygen to water, however it has been quantified that about 1-4% of oxygen fails
to be properly reduced and superoxide is produced as consequence. Dysfunctional ETC leads
to high levels of ROS in mitochondria that are reported as cytotoxic, however this condi‐
tion has been also associated with induction of pro-angiogenic signaling [55]. In vitro and in
vivo treatments with inhibitors of ETC (i.e. rotenone) inhibits VEGF -induced signaling and
vascular walls remodeling [56] suggesting that ETC may play a role in redox signaling in
normal and pathological angiogenesis.
4. Cellular systems for counterbalance oxidative species in angiogenesis:
Natural antioxidants and scavenging systems
4.1. Antioxidant enzymes
In order to limit oxidative stress levels cells are armed with a series of enzymes and molecules.
Important enzymes for degradation of hydrogen peroxide and superoxide are family of
superoxide dismutase (SOD), catalase (CAT), peroxiredoxins (PRX), thioredoxin (TRX) and
gluthatione peroxidase (GPx). All these enzymes play a critical role in modulation redox
signaling.
Superoxide dismutase (SOD) is the most important cellular mechanism of protection against
superoxide anion (O2 -). SOD catalyzes the dismutation of O2 - into hydrogen peroxide (H2O2).
The catalytic reaction of SOD involves metal cations (i.e. Cu, Zn, Mn) as cofactors that
continuously shift between reduced and oxidized forms in the active site of the enzymes. In
humans there are three isoforms of superoxide dismutase enzymes that are distinguished for
their cellular localization: SOD1 (CuZn-SOD) which is localized essentially in the cytosol,
SOD2 (Mn-SOD) which is localized in the mitochondria and SOD3 (CuZn-SOD, also known
as ec-SOD) which is localized in the extracellular matrix. All three isoforms catalyze the same
reaction, which is important, not only to scavenge the cytotoxic effects of superoxide anion
accumulation (i.e. oxidation and inactivation of proteins), but also to prevent the reaction of
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O2 – with nitric oxide (NO) to generate peroxynitrate. In this way these enzymes guarantee the
metabolism of H2O2, important for redox signaling [57]. In the vasculature the signaling of
H2O2 produced by SODs activates multiple pathways important for angiogenesis. The H2O2
generated by SOD3 in the extracellular space favorites VEGFR2 signaling and consequently
modulates angiogenesis. H2O2 produced by SOD3 under conditions of ischemic injury,
protects tissues and promotes neovascularization by enhancing Ras-ERK, PI3kinase-Akt
pathways and VEGF expression [58].
The H2O2 generated by SOD1 is actively produced in endosomes under inflammation signals
and activates NF-kB. Moreover such H2O2 generated by SOD1 is particularly important in
endothelial cells where acts as endothelium–derived hyperpolarization factor (EDHF). It has
been demonstrated that in the tumorigenic context, SOD1 overexpression promotes angio‐
genesis and tumor growth. Also the H2O2 generated by SOD2 is important for endothelium.
It has been demonstrated that SOD2 overexpression favorites Akt pathway activation and
enhances vessels formations in vivo by favoring endothelial cells sprouting. On the contrary,
SOD2 deficiency causes increased mitochondrial O2 – that results in mitochondria damage (i.e.
mtDNA and mitochondrial proteins oxidation) and endothelial dysfunctions [59,60]. Addi‐
tionally, all SODs enzymes modulate vessels homeostasis by influencing EPCs. SOD3-/- mice
show EPCs failure in physiological processes of migration and differentiation. A recent report
indicate that SOD1-deficient EPCs show shortages in migration and ability to generate small
vessels networks [61]. Thus, SODs enzymes play their role in redox signaling by regulating
angiogenesis through H2O2 and protecting EPCs from excess of O2 –.
Catalase (CAT) catalyzes the decomposition of hydrogen peroxide (H2O2) into water and
oxygen by helping the antioxidant machinery in cells. The active site of the enzyme is made
by four porphyry heme groups, that are essential to catalyze the flow of electrons between
atoms. The mechanism of reaction is not jet fully characterized however it is supposed to occur
into two steps: in the first step the iron is reduced with concomitant production of water, in
the second step another molecule of hydrogen peroxide enters into the active site and allows
the re-oxidation of iron with contemporary production of water and oxygen [62]. The balance
of the reaction consists of two molecules of H2O2 that are decomposed into two molecules of
water and one molecule of oxygen. Catalase is intracellular localized, mainly in peroxisomes
of animal and vegetal cells. In addition, there are also data supporting its localization in the
mitochondria and cytosol. Catalase is an enzyme shared between all organisms. All cells
contain catalase, however knock-out animal models do not display severe phenotypes. Also
human patients showing reduced levels of catalase enzymes do not display severe health
disorder [63]. It is supposed that the lack of catalytic activity of catalase may be replaced by
multiple alternative antioxidant systems. The catalase plays an important role in the redox
signaling since it regulates H2O2 levels, which is important for homeostasis of vascular beds.
Catalase of endothelial cells protects smooth muscle cells from oxidative damage of luminal
peroxide [64] and is involved in mechanisms of vessels relaxation [65]. Moreover, it has been
also reported that catalase in combination with SOD play a synergistic role in the regulation
of endothelium permeability. Overexpression of catalase was also applied to breast cancer cells
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in order to down-regulate intracellular ROS levels and make tumor cells more sensitive to
therapy (paclitaxel, etoposide and arsenic triosside) [66].
Peroxiredoxins (PRX) are a family of ubiquitous antioxidant enzymes constituted by several
isoforms. PRX catalytic activity consists in the reduction of cellular hydrogen peroxide and for
some aspects it overlaps with enzyme activity of other antioxidant enzymes (i.e. catalase and
GPx) [67]. However, PRXs differentiate from other antioxidant enzymes for their mechanism
of activity. Their enzymatic active site is constituted by cysteine amminoacids that metabolize
H2O2 by cycling between oxidation and reduction reactions. When a molecule of hydrogen
peroxide enters, the active Cys-SH oxides into Cys-SOH. This intermediate form can be further
oxidized to Cys-SO2H. The recycling of cysteine is mediated by glutathione, ascorbic acid or
sulfiredoxins. According with the setting of the active site PRX are divided into three groups.
The first two groups are Typical 2-Cys-PRX and Atypical 2-Cys-PRX, according with folding
structure, and both contains two residues of Cys in their active site are. The third class, 1-Cys-
PRX contains only one Cys in the active site. Besides the difference in the number of active
cysteine, all PRXs act as intracellular H2O2 scavengers. PRXs are localized primarily in the
cytosol, but they are localized also in intracellular organelles (peroxisomes, mitochondria)
where they take part to regulation of H2O2 levels and redox signaling [68,69]. In vivo knockout
mice for PRX-VI are more sensitive to oxidative stress under hyperoxia exposure, while
knockout mice for PRX-I and PRX-II develop severe blood cells disease (hemolytic anemia and
hematopoietic cancer) [70,71]. The role of PRXs in redox signaling in cardiovascular system is
still not clear.
Thioredoxins (TRX) are a small class of antioxidant enzymes composed of two isoforms: TRX1,
which is primarily localized in the cytosol and nucleus, and TRX, which is found in mitochon‐
dria. All TRX enzymes are ubiquitously expressed and are characterized by a dithiol-disulfide
site. The active site of TRX contains a specific and highly conserved motif with two residues
of Cysteine that are essentials to reduce oxidized proteins and buffer ROS. TRX can be
continuously reconverted from oxidized form into reduced form thanks to thioredoxin
reductase enzymes activity. The TRX system is modulated by an endogenous inhibitor protein,
called TXNIP (TRX-interacting protein), that prevents TRX to form disulfides [72]. The TRX
system has been shown to be essential for life since the knockout mice of either isoform is lethal
for embryo development [73,74]. Moreover endothelium specific Trx2 transgenic mice as well
as mice overexpressing Trx1 demonstrate a crucial role of this class of enzymes in buffering
oxidative stress in endothelial cells. TRX1 can modulate different cellular processes involved
with endothelial cell homeostasis and angiogenesis. In endothelial cells TRX1 prevents
degradation of HIF1α and consequently modulate VEGF expression facilitating pro-angio‐
genic processes. Moreover, TRX1 can regulate proliferation and migration of endothelial cells
by modulation of NF-kB activity and upregulation of matrix metalloproteases (MMPs). TRX2
have been demonstrated to play also a specific role in endothelial cells by inducing angiogen‐
esis and arteriogenesis in pathological conditions (i.e. murine model of ischemia) [75]. The
importance of this antioxidant system for promoting angiogenesis has been considered for
development of anticancer drugs. In vitro studies performed with TRX inhibitors (i.e. PMX464,
AJM290) confirm the pivotal role of this class of enzymes in preventing endothelial cell
proliferation and differentiation [76].
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Glutathione peroxidases (GPx) are a family of enzymes that catalyze the reduction of
hydrogen peroxide and organic hydroperoxides to water. The reaction consists in the oxidation
of monomeric glutathione to glutathione disulfide with the involvement of a selenic acid
group. Oxidized glutathione molecules are then reduced by a specific glutathione reductase
[77]. In humans there are eight isoforms of glutathione peroxidases with different intracellular
localizations and different relative abundance in tissues. Human GPx1, GPx2, GPx3, GPx4 and
Gpx6 are different from other isoforms for containing seleno-cysteines in their catalytic sites,
which identifies them as seleno-proteins. All GPxs play a fundamental role in the antioxidant
molecular network as peroxide scavenging enzymes, however specific notes are reported for
different isoforms. GPx4 has been identified mainly as phospholipid hydroperoxidase since it
not only reduces peroxides but it is also efficient in reducing phospholipids, cholesterol and
lipoproteins hydroperoxide [78]. In pig livers GPx4 activity was reported for inhibition of lipid
peroxidation [79] and curiously crucial for sperm maturation [80]. GPx3 is produced in the
tubules of kidney and secreted in extracellular fluids as well as in the plasma, but its antioxi‐
dant activity does not seem to be essential since GPx3-/- mice do not show abnormal phenotype
[81]. Recent studies on GPx3 promoter regulation suggest that its expressivity is implicated in
epithelial tumor development but a specific role needs to be addressed [82]. GPx2 is expressed
in the gastrointestinal system and is supposed to play a key role as antioxidant enzyme in the
gut. Also, GPx2-/- mice do not show abnormal phenotype [83] but in vitro and in vivo data
regarding loss of GPx2 expression report a role for GPx2 in regulation of inflammation-
mediated carcinogenesis and for supporting growth of established tumors. Among the GPxs
isoforms the most studied and characterized is GPx1, which is also the most abundant one. It
is ubiquitously expressed and it is localized mainly in the cytosol and in mitochondria. GPx1
is believed to be the most important peroxide scavenger in the family [84], even tough also
GPx1-/- mice are not lethal and develop normally [85]. In vivo data indicate that the loss of this
enzyme is correlated with high oxidative damage condition. Loss of GPx1 in condition of
cerebral inflammation increases pro-oxidative species level and favors interactions between
leukocytes and endothelial cells of cerebral microvasculature [86]. Loss of GPx1 in human
microvascular cells as well as in GPx1-/- mice favors endothelium response to lipo-polisaccaride
pro-oxidant stimuli favoring intracellular reactive oxygen species accumulation and altering
expression of adhesion molecules. Levels of GPx1 are also reported to modulate angiogenic
endothelial progenitor cells (EPCs) in correlation with aging. EPCs of old subjects, that have
impaired GPx1 levels, are more sensitive to oxidative damage [87].
4.2. Antioxidant molecules
Recent evidence suggests that many natural antioxidant molecules contained in foods or
plants have beneficial effects against tumor progression. Polyphenols as well as terpenoids act
on overall oxidative stress levels. By modulation of cytokines, metabolizing enzymes, growth
factors and various molecules in redox signaling, antioxidants regulate pathways for tumor
angiogenesis. Natural polyphenols are a class of compounds constituted by molecules
containing repetitive units of phenols that characterize them with antioxidant properties.
Polyphenols are naturally present in vegetal derived foods (i.e. fruits, tea, red wine, honey,
olive oil) and can be assumed directly with the diet [88]. Data regarding alimentary habits
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correlate black tea assumption with beneficial effects on endothelium dysfunctions in indi‐
viduals with chronic heart disease and hypercholesterolemia [89]. In vitro studies on endo‐
thelial cells demonstrate polyphenols modulate redox signaling by regulation of arachidonic
acid cascade. In particular, it has been reported that polyphenols from virgin olive oil and red
wine reduce significantly angiogenesis by inhibition of cyclooxigenase2 (COX2) and activation
of redox sensitive NF-kB pathway [90]. Microarray data and RT-PCR analyses show that
treatment of endothelial cells (HUVEC) with resveratrol (contained in red wine) can upregu‐
late eNOS and decrease the levels of endothelin-1, suggesting a protective role against
endothelium contractions. Moreover, resveratrol exerts a protective effects on endothelium as
assed also under pro-oxidative state (in presence of H2O2). Together with anthocyanin, also
polyphenols (contained in berries that have red pigments) are reported to have an antioxidant
positive effect for cardiovascular system. Recently, anthocyanins from six berries extracts have
been mixed in a formula (OptiBerry), which in vitro exhibits anti-angiogenic properties on
human microvascular endothelial cells and also in vivo impairs endothelioma cells for tumor
growth [91].
Among lipids there are also very important antioxidant molecules. They are naturally present
in plants like carotenes (retinol and b-carotene), alpha-tocopherol (also known as Vitamin E)
or synthetized by animal cells, like CoenzymeQ10. The characteristic lipid character of these
molecules allows them to localize in cell membranes (intracellular organelles and plasma
membrane) where they can buffer lipid radicals and prevent reactions of peroxidation.
Antioxidant Vitamin E properties for lipid peroxidation were efficiently assayed in GPx4-/-
mice [92]. Carotenoids are tetraterpenoid pigments contained exclusively in plant cells that
can be assumed with diet and act as terminal antioxidant molecules, once oxidized they can
not be “re-used” from cells [93]. CoenzymeQ10 (CoQ10) is a terpenoid molecule whose
antioxidant activity has been reported for maintenance of healthy cardiovascular system.
Recent clinical trials have also show the use of CoQ10 for lowering blood pressure. At the
present there are not evidences regarding the involvement of lipid antioxidant molecules in
conditions of tumor angiogenesis [94].
Several other antioxidant genes are normally induced in cells to shield against dangerous
deregulation of redox balance. Among those which play a key role in angiogenesis we can find
heme-oxygenase-1 (HMOX-1) and nuclear factor erythroid 2 (NRF2) [95]. Upregulation of
these genes are correlates to tumor metastasis and progression suggesting how oxidative stress
is a condition implicated in tumor angiogenesis [96].
5. Angiogenic molecules regulated by redox signaling
Vascular Endothelial Growth Factor (VEGF) family encloses six glycoproteins: VEGF-A,
VEGF-B, VEGF-C, VEGF-D AND VEGF-E, all of them belong to a superfamily of growth
factors. Endothelial cells have three types of specific VEGF receptors: VEGFR-1 (Flt-1),
VEGFR-2 (KDR, Flk-1), VEGFR-3 (Flt-4). Signaling mediated by VEGF and respective receptors
has been characterized as one of the most powerful factors for induction and maintenance of
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angiogenesis in a series of physiological as well as pathological (i.e. tumor) angiogenesis
[97,98]. Among the multiple mechanisms of VEGF signaling regulation we can also found its
redox state. Modulators of redox state as the concentration of oxygen directly regulates VEGF
levels. VEGF promoter contains a hypoxia responsive element that can be bound by transcrip‐
tion factors HIF-1α- HIF1β under conditions of low oxygen concentration in vascular vessels
(hypoxia). In vitro studies by using human genome array on pulmonary artery endothelial
cells maintained in hypoxia for 24hours report up-regulation of expression of VEGF genes.
Accordingly, in vivo hypoxia conditions induce VEGF and VEGFR-1/2 expression [99,100]. It
has been also reported that modulation of redox state by NO levels regulates angiogenesis and
tumor progression through modulation of VEGF–VEGFR signaling. In vitro treatments of
human tumor cells with NO-donor (i.e. SNAP) or NO-generating compounds upregulate
VEGF expression and stimulate angiogenesis [101]. Further specifications about VEGF
modulation by NO are related to endothelial NOS activity.
Angiopoietins  (Ang)  are  a  group of  four  growth factors  (Ang-1,  Ang-2,  Ang-3,  Ang-4)
involved in blood vessels formation. Signaling mediated by angiopoietins and their spe‐
cific receptors (TIE, tyrosine kinases receptor) has been characterized as key factors in an‐
giogenesis  [102].  They  are  particularly  sensitive  to  endothelium  environment  since
angiopoietins are modulated by pro-oxidative species. In vitro and in vivo studies in en‐
dothelial  cells  report  Ang1 is  induced by hydrogen peroxide and abrogation of  catalase
activity relates  to  low ability  in  cell  migration and vessels  formation [103].  Also,  angio‐
poietin-like proteins (ANGPTL) are involved in redox signaling in tumor conditions. Up‐
regulation  of  expression  of  ANGPL4  promotes  NADPH  oxidases  activity  causing  an
alteration  in  relative  abundance  of  superoxide  anion  over  hydrogen  peroxide.  Finally,
such redox alteration induces tumor cells escape from anoikis and promotes survival via
specific activation of PI3K/PKBα/ERK pathway [104].
Vascular  Endothelial  (VE)-Cadherin  is  an  adhesion  protein  in  the  adherent  junction
complexes  of  endothelial  cells  and has  been characterized as  the  major  system for  con‐
trolling endothelial  cells junctions [105].  VE-Cadherin controls vascular permeability and
remodeling of blood vessels also under mechanical  stimuli  (shear forces)  [106].  VE-Cad‐
herin  regulation  is  sensitive  to  pro-angiogenic  factors,  in  particular  to  VEGF [107].  VE-
Cadherin is  also directly regulated by redox signaling pathway.  In vitro assays showed
that  resveratrol  promotes  proliferation  and  migration  of  cerebral  endothelial  cells  by
modulation of VE-cadherin as result of activation of MAPK/ERK pathway and NO upre‐
gulation [108]. It has also been demonstrated that resveratrol control initiation of arterio‐
genesis  by  blocking  oxidative  stress  dependent  phosphorylation  of  VE-Cadherin  [109].
Interestingly, it  is also reported that nitrate concentration contributes to control VE-Cad‐
herin  stability  in  adherent  junction  of  human  primary  endothelial  cells  (HUVEC)  and
prevents blood vessel leakage [110].
Nuclear factor-kB (NF-kB) is a transcriptional factor that promotes tumor growth and
invasiveness by activation of angiogenic molecules in endothelial cells [111]. Using a zebrafish
animal model it has been shown that in vivo NF-kB inhibition causes loss of vascular integrity
and interferes with physiologic vessels morphology [112]. Inhibition or negative modulation
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of NF-kB is considered an alternative approach to block pathological angiogenesis. Among
inhibitors of NF-kB it has been reported evidence for antioxidant molecules. In vitro treatments
of cells with pro-oxidative species (hydrogen peroxide, LPS, TNF-α ) activates NF-kB, while
contemporary antioxidants addiction inhibit its response [113,114]. NF-kB activation can also
be impaired by N-acetylcysteine (that acts in the NO pathway), terpenoids (vitamin E) and
mitochondria-specific antioxidant (rotenone) [115,116]. At the present it is not fully clarified
as antioxidants interact with NF-kB and inactivate it. It is supposed they can act indirectly by
altering different molecules that interact with NF-kB on redox pathways or directly by
inhibition of IKK kinase activity [117].
6. Conclusion: Manipulating redox signaling as anti-tumor angiogenesis
therapy
Increased generation of reactive oxygen species (ROS) and an altered redox status have long
been observed in cancer cells, and recent studies suggest that this biochemical property of
cancer cells can be exploited for therapeutic benefits. Cancer cells in advanced stage tumors
frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it
might be possible to preferentially eliminate these cells by pharmacological ROS insults [118].
Reactive oxygen species (ROS) might function as a double-edged sword in endothelial cells.
A moderate increase of ROS may promote cell proliferation and survival. However, when the
increase of ROS reaches a certain level (the toxic threshold), it may overwhelm the antioxidant
capacity of the cell and trigger cell death. Under physiological conditions, normal endothelial
cells maintain redox homeostasis with a low level of basal ROS by controlling the balance
between ROS generation (pro-oxidants) and elimination (antioxidant capacity). Endothelial
cells in normal vessels can tolerate a certain level of exogenous oxidative stress owing to their
‘reserve’ antioxidant capacity, which can be mobilized to prevent the ROS level from reaching
the cell-death threshold. In In endothelial cells of tumor vessels the increase in ROS generation
from metabolic abnormalities and oncogenic signaling may trigger a redox adaption response.
This response leads to an upregulation of antioxidant capacity and a shift of redox dynamics
that maintain the ROS levels below the toxic threshold. As such, tumor angiogenic cells would
be more dependent on the antioxidant system and more vulnerable to further oxidative stress
induced by exogenous ROS-generating agents or compounds that inhibit the antioxidant
system. A further increase of ROS stress in these cancer cells using exogenous ROS-modulating
agents is likely to cause elevation of ROS above the threshold level, leading to cell death. This
might constitute a biochemical basis to design therapeutic strategies to selectively kill tumor
angiogenic cells using ROS-mediated mechanisms [119-121].
The role of redox signaling in tumor angiogenesis is not yet completely characterized.
Although converse mechanisms are postulated about how oxidative species recruit new blood
vessels for tumor progression, it is well established redox signaling modulates angiogenesis.
Analysis and characterization of molecules that sustain redox signaling is a new opportunity
for set up innovative strategies of anti-cancer therapy (Figure 1).
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Figure 1. Schematic representation of redox mechanisms in tumor angiogenesis. Multiple stimuli coming from
tumor microenvironment (growth factor, prostanoids, oxygen tension, mechanical forces) induce specific activation of
intracellular pro-oxidant enzymes (NADPH oxidase, xantine oxidoreductase, uncoupled eNOS). Consequently, raising
levels of oxygen and nitrogen pro-oxidant species (ROS/RNS) modulate the activation of multiple cellular pathways by
acting on molecular and transcriptional factors. Signaling induced by oxidative species results mainly in endothelial
cells motility and proliferation towards vascular remodeling and formation of new blood vessels. HIF-1α hypoxia-indu‐
cible transcription factor; ETS E-twenty six family transcription factor; AP-I activator protein 1; p53 tumor suppressor
protein; NF-kB nuclear factor – kB. PKC protein kinase C; PI3K phosphatidylinositol3-OH kinase; PTP protein tyrosine
phosphatase; SRC tyrosine protein kinase; p38MAPK p38 mitogen-activated protein kinase; Akt serine/threonine-spe‐
cific protein kinase; ERK1/2 extracellular signal-regulated kinases; MMP matrix metalloproteinase; VE–Cadherin: vas‐
cular endothelial-cadherin; VEGFR vascular endothelial growth factor receptor; ICAM intracellular adhesion molecule
1; VACAM vascular cell adhesion molecule 1.
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